Johnson & Johnson (NYSE:JNJ) Shares Sold by Accordant Advisory Group Inc

Accordant Advisory Group Inc lowered its position in Johnson & Johnson (NYSE:JNJ) by 47.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,896 shares of the company’s stock after selling 9,782 shares during the quarter. Johnson & Johnson makes up approximately 1.4% of Accordant Advisory Group Inc’s portfolio, making the stock its 23rd biggest position. Accordant Advisory Group Inc’s holdings in Johnson & Johnson were worth $1,766,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Retirement Planning Group LLC raised its stake in shares of Johnson & Johnson by 2.6% during the first quarter. Retirement Planning Group LLC now owns 5,950 shares of the company’s stock worth $941,000 after purchasing an additional 153 shares during the last quarter. Quad Cities Investment Group LLC lifted its stake in shares of Johnson & Johnson by 2.9% in the 1st quarter. Quad Cities Investment Group LLC now owns 2,854 shares of the company’s stock worth $451,000 after acquiring an additional 80 shares during the period. Evanson Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 1.2% in the first quarter. Evanson Asset Management LLC now owns 13,731 shares of the company’s stock valued at $2,172,000 after acquiring an additional 169 shares in the last quarter. Beech Hill Advisors Inc. increased its stake in shares of Johnson & Johnson by 2.3% during the first quarter. Beech Hill Advisors Inc. now owns 19,831 shares of the company’s stock worth $3,137,000 after acquiring an additional 439 shares during the period. Finally, DLK Investment Management LLC raised its holdings in Johnson & Johnson by 4.4% during the first quarter. DLK Investment Management LLC now owns 31,527 shares of the company’s stock worth $4,987,000 after purchasing an additional 1,326 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Citigroup increased their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Finally, TD Cowen lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $165.86 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The stock has a market cap of $399.17 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The business has a fifty day moving average of $163.29 and a 200-day moving average of $154.92.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.66 EPS. As a group, analysts predict that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 2.99%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.